Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
Por:
Wollenberg, A, Marcoux, D, Silverberg, JI, Aoki, V, Baselga E, Zhang, HX, Levit, NA, Taieb, A and Rossi, AB
Publicada:
1 may 2022
Ahead of Print:
31 may 2022
Resumen:
This post hoc analysis examined SCORing Atopic Dermatitis (SCORAD) outcomes in 471 paediatric patients (children age 6-<12 years, n = 304; adolescents age 12-<18 years, n = 167) with atopic dermatitis treated with dupilumab, +/- topical corticosteroids, in two 16-week phase 3 randomized controlled trials and a 1-year interim data cut of a subsequent open-label extension study. Paediatric patients treated with dupilumab (+/- topical corticosteroids) had significantly lower SCORAD, objective SCORAD (o-SCORAD), and individual SCORAD components from week 3 to 16 compared with placebo (+/- topical corticosteroids) in the randomized controlled trials. The results were sustained or continuously improved over 1 year of open-label treatment with dupilumab +/- topical corticosteroids. SCORAD-50 was achieved in almost all patients (91.3-91.8%) by week 52 with continued dupilumab treatment across age groups. Almost all (> 86%) patients achieved mild or absent pruritus and sleep loss at week 52. In conclusion, dupilumab +/- topical corticosteroids resulted in rapid and significant improvements in all aspects of SCORAD analysed, and the results were sustained over 1 year.
Filiaciones:
Wollenberg, A:
Ludwig Maximilians Univ Munchen, Munich, Germany
Marcoux, D:
Univ Montreal, Dept Pediat, Div Dermatol, Montreal, PQ, Canada
Silverberg, JI:
George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA
Aoki, V:
Univ Sao Paulo, Dept Dermatol, Sch Med, Sao Paulo, Brazil
Baselga E:
Hosp St Joan de Deu, Dermatol, Barcelona, Spain
Zhang, HX:
Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
Levit, NA:
Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
Taieb, A:
Univ Bordeaux, Inserm U1035, Talence, France
Dermatology, Bordeaux, France
CHU Bordeaux, Bordeaux, France
Rossi, AB:
Sanofi, 450 Water St, Cambridge, MA 02139 USA
Green Submitted, gold
|